Phase 4 Completed N=15 Randomized Triple-blind Treatment

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

Allergic Rhinitis

Source: ClinicalTrials.gov NCT00791973 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2014

Primary outcomePrimary: Change in Tryptase Level From Baseline to Post-antigen Challenge — 0; 2.31 mcg/L — p=0.33

Summary

The purpose of this study is to help us to a better understanding of how nose and eye symptoms are related in patients with allergies.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Tryptase Level From Baseline to Post-antigen Challenge	0; 2.31	0.33
SECONDARY Total Eye Symptom Scores After Antigen Challenge	3; 3	0.14

Eligibility Criteria

Inclusion Criteria

Males and females between 18 and 45 years of age.
History of grass and/or ragweed allergic rhinitis.
Positive skin test to grass and/or ragweed antigen.
Positive response to screening nasal challenge.

Exclusion Criteria

Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
Pregnant or lactating women.
Upper respiratory infection within 14 days of study start.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00791973). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.